Philip Leming
Hematology & Oncology · Cincinnati, OHNPI 1679569842
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (35.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 36.3% of the total. Reporting peaked in 2021 at $2,676 and has fallen 89.0% since, to $294 in 2025.
Across 117 payments — averaging $62.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$3K
- Array Biopharma Inc$3K
- E.r. Squibb & Sons, L.L.C.$385
- Merck$238
- AstraZeneca$194
- Immunocore Limited$138
- plus $1K from 22 others
Across 10 payments — averaging $386.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3K
- E.r. Squibb & Sons, L.L.C.$487
- Incyte Corporation$181
- Merck$98
What the payments were for
- Consulting fees$2,62536%
- Speaking & faculty fees$2,52034%
- Food & beverage$2,16330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 3 | $2,652 |
| Array Biopharma Inc | 6 | $2,602 |
| E.r. Squibb & Sons, L.L.C. | 31 | $385 |
| Merck | 13 | $238 |
| AstraZeneca | 8 | $194 |
| Immunocore Limited | 2 | $138 |
| Tempus AI, Inc | 2 | $127 |
| Astellas Pharma US Inc | 5 | $97 |
| Novartis | 7 | $96 |
| Daiichi Sankyo Inc. | 5 | $96 |
| Gilead | 4 | $88 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $73 |
| Johnson & Johnson(2 entities) | 4 | $72 |
| Sanofi | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $55 |
| Pfizer | 4 | $51 |
| Foundation Medicine, Inc. | 1 | $39 |
| Iovance Biotherapeutics, Inc. | 1 | $35 |
| Bristol Myers Squibb | 2 | $34 |
| AVEO Pharmaceuticals, Inc. | 2 | $32 |
| Lexicon Pharmaceuticals, Inc. | 2 | $25 |
| Eisai Inc. | 1 | $24 |
| Blueprint Medicines Corporation | 1 | $19 |
| Tolmar, Inc. | 1 | $17 |
| Progenics Pharmaceuticals, Inc. | 1 | $16 |
| Mylan Institutional Inc. | 1 | $16 |
| Puma Biotechnology, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,308 in reported general payments places this provider in the 65th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.